Medical technology company Hologic (NASDAQ: HOLX) will be reporting earnings this Thursday after market hours. Here’s what you need to know.

Hologic beat analysts’ revenue expectations by 1.5% last quarter, reporting revenues of $1.05 billion, up 6.2% year on year. It was a strong quarter for the company, with a solid beat of analysts’ constant currency revenue estimates and a decent beat of analysts’ revenue estimates.

Is Hologic a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Hologic’s revenue to grow 4.8% year on year to $1.07 billion, improving from its flat revenue in the same quarter last year. Adjusted earnings are expected to come in at $1.10 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Hologic has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 1.2% on average.

Looking at Hologic’s peers in the healthcare equipment and supplies segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Neogen’s revenues decreased 2.8% year on year, beating analysts’ expectations by 7.2%, and Intuitive Surgical reported revenues up 18.8%, topping estimates by 1%. Neogen traded up 30.4% following the results while Intuitive Surgical’s stock price was unchanged.

Read our full analysis of Neogen’s results here and Intuitive Surgical’s results here.

Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices up 1.4% on average over the last month. Hologic’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $76.92 (compared to the current share price of $75.20).

P.S. STOP buying the AI stocks everyone's talking about. The real money? It’s in the profitable pick nobody’s watching yet. We’ve identified an AI profit machine that’s flying under Wall Street’s radar—for now. We can’t keep this research public forever—grab your FREE copy before we pull it offline. GO HERE NOW.